Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib with Chemotherapy in Malignant Mesothelioma
NCT01211275Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2009
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of axitinib in malignant pleural mesothelioma (MPM) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Impact of axitinib on histology samples. Started May 2009; status: completed.
02
Drugs
axitinib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01211275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211275.